ALN-PNP

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Liver DiseaseAlcoholic Fatty Liver DiseaseMetabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

221 competitors in Liver Disease

#DrugCompanyPhaseTrials

1

Mounjaro

Eli Lilly

Phase 3

—2

Neurontin

VViatris Specialty LLC

Phase 3

13

Inderal

WWyeth-Lederle Vaccines

Phase 3

14

Viagra

VViatris Specialty LLC

Phase 3

15

Sandostatin

Sun Pharma

Phase 3

16

Neupogen

EEastern Cooperative Oncology Group

Phase 3

—7

Promacta

GSK

Phase 2

38

Retatrutide

Eli Lilly

Phase 3

—9

Ozempic

Novo Nordisk

Phase 2

110

Jardiance

Boehringer Ingelheim

Phase 2

2Show 36 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Alcoholic Fatty Liver Disease1 trial

A Trial to Learn if Receiving ALN-PNP siRNA is Safe and Well Tolerated, and How it Works in Adult Participants With Nonalcoholic Fatty Liver Disease (NAFLD) and a Genetic Risk Factor

Completed·Regeneron·Phase 1·NCT06024408·9 enrolled

Liver Disease1 trial

A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Recruiting·Regeneron·Phase 1·NCT05648214·156 enrolled

Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)1 trial

A Two-Part, Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study of ALN-PNP With and Without a GLP1R Agonist in Adults With Homozygous PNPLA3-Related Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Recruiting·Regeneron·Phase 2·NCT07527910·204 enrolled

Details

Drug Info

Related News